NEVVI Medicare utilization intelligence
or

← back

Provider profile

TAN, WINSTON MD

Hematology-Oncology · NPI 1245229772 · JACKSONVILLE, FL

1
Groups
53
Codes · 2024
54,562
Disclosed services

TAN, WINSTON is a Hematology-Oncology in JACKSONVILLE, FL, a member of 1 medical group, who billed 53 distinct codes to Medicare Part B in 2024.

Groups: MAYO CLINIC JACKSONVILLE (JACKSONVILLE, FL)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

54,562
disclosed services
53
codes billed to Medicare Part B
Prior year · CY2023 117,920 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J1453 Injection, fosaprepitant, 1 mg
J9271 Injection, pembrolizumab, 1 mg
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
J9299 Injection, nivolumab, 1 mg
Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J9267 Injection, paclitaxel, 1 mg
J0897 Injection, denosumab, 1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
J2469 Injection, palonosetron hcl, 25 mcg
Q5118 Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg
J9041 Injection, bortezomib, 0.1 mg
J2405 Injection, ondansetron hydrochloride, per 1 mg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96375 Injection of additional new drug or substance into vein
J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
J9395 Injection, fulvestrant, 25 mg
Q5108 Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg
96413 Administration of chemotherapy into vein, 1 hour or less
J9060 Injection, cisplatin, powder or solution, 10 mg
J9045 Injection, carboplatin, 50 mg
36591 Collection of blood sample from implanted device
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
J3480 Injection, potassium chloride, per 2 meq
J9190 Injection, fluorouracil, 500 mg
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
J7030 Infusion, normal saline solution , 1000 cc
96361 Infusion into a vein for hydration, each additional hour
96372 Injection of drug or substance under skin or into muscle
J3475 Injection, magnesium sulfate, per 500 mg
96417 Administration of additional new drug or substance into vein, 1 hour or less
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
J1200 Injection, diphenhydramine hcl, up to 50 mg
J3489 Injection, zoledronic acid, 1 mg
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
96415 Administration of chemotherapy into vein, each additional hour
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
96374 Injection of drug or substance into vein
96360 Infusion into a vein for hydration, 31-60 minutes
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
99211 Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional
96411 Administration of additional new drug or substance into vein using push technique
96409 Administration of chemotherapy into vein using push technique
J1720 Injection, hydrocortisone sodium succinate, up to 100 mg
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.